Resultados de la búsqueda 1-10 de 12329 para triple negative breast cancer

  1. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast ...

  2. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...

  3. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...

  4. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    ... Triple-Negative Breast Cancer. Rochester, Minn., Scottsdale/Phoenix, Ariz ... Triple-Negative Breast Cancer. Rochester, Minn., Scottsdale/Phoenix, Ariz ...

  5. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    ... Triple-Negative Breast Cancer. Rochester, Minn., Scottsdale/Phoenix, Ariz ... Triple-Negative Breast Cancer. Rochester, Minn., Scottsdale/Phoenix, Ariz ...

  6. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast ...

  7. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...

  8. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...

  9. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...

  10. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) ...